Indapamide NCT07765212 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 11 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 2

Clinical phase

Not yet recruiting

Recruitment status

75

Planned enrollment

2028-09-01

Primary-completion proxy

Executive view

NCT07765212 evaluates Indapamide in Multiple Sclerosis, Secondary Progressive. The disclosed sponsor is Sponsor not reported, the design is Interventional, and the geographic footprint is Geography not reported. The first listed primary endpoint is Number of participants with 20% or more worsening in timed 25 foot walk between the Baseline and the 12 Months follow-up study visit., assessed over 12 months.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07765212 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Multiple Sclerosis, Secondary Progressive landscape. Drug & Asset MCP drug_fetch was queried for Indapamide, while Company & Deal Intelligence MCP organization_fetch was queried for Sponsor not reported.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT07765212	Indapamide	Phase 2 / Not yet recruiting	Sponsor not reported	Geography not reported	Number of participants with 20% or more worsening in timed 25 foot walk between the Baseline and the 12 Months follow-u… 12 months	2028-09-01
NCT07804004	Zugocaptagene Geleucel	Phase 1/2 / Not yet recruiting	CRISPR Therapeutics AG	Geography not reported	To evaluate the safety of CTX112 in adult participants with neurological autoimmue disorders, including PMS, relapsing… From CTX112 infusion up to 28 days post infusion	2029-12-30
NCT07805473	[18F]-D2-deprenyl	Not Applicable / Not yet recruiting	Consorci Mar Parc de Salut de Barcelona	Spain	Diagnostic Accuracy of [18F]F-DED PET for Detecting Chronic Active Lesions Baseline (PET/CT and MRI performed within 1 week)	2029-12-01

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT07765212 is a Phase 2, not yet recruiting study with 75 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.

The primary endpoint is “Number of participants with 20% or more worsening in timed 25 foot walk between the Baseline and the 12 Months follow-up study visit.” over “12 months.” The retrieved endpoint description is: The T25FW is the time it takes for the participant to walk 25 feet, averaged over two trials. Significant worsening is defined as a more than or equal to 20 percent increase in the T25FW..

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 75 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

4 recent result records were selected as contextual evidence for Multiple Sclerosis, Secondary Progressive. These records do not establish direct evidence for NCT07765212 unless the registration number matches.

A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients…

Phase 3; n=236; Serum Ocrelizumab Area Under the Concentration-Time Curve Over the First 12 Weeks (AUCW1-12) After SC Administration(Mean): Geometric Mean Ratio = 1.2851(90% CI, 1.2258 - 1.3473); Serum Ocrelizumab Area Under the Concentration-Time Curve Over the First 12 Weeks (AUCW1-12) After SC Administration(Mean) = 3500 micrograms/milliliters*day (µg/mL*day) (Standard Deviation, 914) Source: https://clinicaltrials.gov/ct2/show/results/NCT05232825

Phase II Prospective Trial of Vaccine Responses in Childhood Cancer Survivors

Phase 2; n=75; Percentage of Participants With Protective Antibody Titers After Vaccination = 93.5 percentage of pts ; Percentage of Participants With Protective Antibody Titers After Vaccination = 93.5 percentage of pts Source: https://clinicaltrials.gov/ct2/show/results/NCT00505063

A Phase IIIB Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary P…

Phase 3; n=769; Time to Onset of 12-week Composite Confirmed Disability Progression (cCDP12)(Median) = 158.7 weeks (95% Confidence Interval, 120.0 - NA); Time to Onset of 12-week Composite Confirmed Disability Progression (cCDP12)(Median) = 169.0 weeks (95% Confidence Interval, 144.1 - NA) Source: https://clinicaltrials.gov/ct2/show/results/NCT04548999

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

No exact Drug & Asset MCP profile was returned for the protocol wording “Indapamide.” The report therefore avoids inferring modality, target or global development stage from the name alone.

No exact Company & Deal Intelligence profile was returned for Sponsor not reported. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Indapamide is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT07765212
Protocol source: https://clinicaltrials.gov/study/NCT07765212
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 11 September 2026.

Indapamide in Multiple Sclerosis, Secondary Progressive is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Number of participants with 20% or more worsening in timed 25 foot walk between the Baseline and the 12 Months follow-up study visit. and 2028-09-01 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP